Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patrick Mayeux is active.

Publication


Featured researches published by Patrick Mayeux.


Journal of Biological Chemistry | 1998

Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein.

Frédérique Verdier; Stany Chrétien; Odile Muller; Paule Varlet; Akihiko Yoshimura; Sylvie Gisselbrecht; Catherine Lacombe; Patrick Mayeux

Cis is an Src homology 2 domain-containing protein, which binds to the erythropoietin receptor and decreases erythropoietin-stimulated cell proliferation. We show that Cis associates with the second tyrosine residue of the intracellular domain of the erythropoietin receptor (Tyr401). Two forms of Cis with molecular masses of 32 and 37 kDa were detected, and we demonstrate that the 37-kDa protein resulted from post-translational modifications of the 32-kDa form. Anti-ubiquitin antibodies recognized the 37-kDa form of Cis and the proteasome inhibitorsN-acetyl-leucyl-leucyl-norleucinal and lactacystin inhibited its degradation, showing that the 37-kDa form of Cis is a ubiquitinated protein, which seems to be rapidly degraded by the proteasome. In erythropoietin-stimulated UT-7 cells, the activation of the erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) was transient and returned to basal levels after 30–60 min of erythropoietin stimulation. In contrast, these proteins remained strongly phosphorylated, and STAT5 remained activated for at least 120 min in the presence of proteasome inhibitors. These experiments demonstrate that the proteasomes are involved in the down-regulation of the erythropoietin receptor activation signals. Because the proteasome inhibitors induced the accumulation of both the ubiquitinated form of Cis and the Cis-erythropoietin receptor complexes, our results suggest that the ubiquitinated form of Cis could be involved in the proteasome-mediated inactivation of the erythropoietin receptor.


Archive | 2013

erythroid progenitor proliferation Critical role for PI 3-kinase in the control of erythropoietin-induced

Sylvie Gisselbrecht; Patrick Mayeux; Catherine Lacombe; Didier Bouscary; Frédéric Pène; Yann-Erick Claessens; Odile Muller; Stany Chrétien


Archive | 2013

with myelodysplastic syndromes: evidence for Fas-dependent apoptosis In vitro proliferation and differentiation of erythroid progenitors from patients

Catherine Lacombe; Francois Dreyfus; Patrick Mayeux; Didier Bouscary; Jean-Michel Dupont; Françoise Picard; Josiane Melle


Archive | 2013

patients favorable prognostic factor in de novo acute myelogenous leukemia Constitutive phosphoinositide 3-kinase/Akt activation represents a

Francois Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary; Pascale Cornillet-Lefebvre; Bruno Lioure; Valérie Ugo; Odile Blanchet; Norbert Ifrah; Francis Witz; Jerome Tamburini; Caroline Elie; Valerie Bardet; Nicolas Chapuis; Sophie Park; Philippe Broët


Archive | 2013

therapeutic inhibition of both pathways factor-1 receptor signaling in acute myeloid leukemia: rationale for phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth Mammalian target of rapamycin (mTOR) inhibition activates

Norbert Ifrah; Francois Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary; Jerome Tamburini; Nicolas Chapuis; Valerie Bardet; Pierre Sujobert; Lise Willems


Archive | 2013

pathways acute myeloid leukemia: rational for therapeutic inhibition of both mTORC1 inhibition activates PI3K/Akt by up-regulating IGF-1R signaling in

Francois Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary; Jerome Tamburini; Nicolas Chapuis; Valerie Bardet; Lise Willems


Archive | 2013

β by Transforming Growth Factor- Downregulation of Interleukin-12 (IL-12) Responsiveness in Human T Cells

Giorgio Trinchieri; Salem Chouaib; Cécile Pardoux; Xiaojing Ma; Stephanie Gobert; S. Pellegrini; Patrick Mayeux


Archive | 2013

favourable prognostic factor in de novo AML patients Constitutive Phosphoinositide-3kinase/AKT activation represents a

Patrick Mayeux; Catherine Lacombe; Didier Bouscary Cornillet-Lefebvre; Bruno Lioure; Valérie Ugo; Odile Blanchet; Norbert Ifrah; Francis Witz; Caroline Elie; Valerie Bardet; Nicolas Chapuis; Philippe Broët


Archive | 2013

treating acute myeloid leukemia Inhibiting glutamine uptake represents an attractive new strategy for

Catherine Lacombe; Patrick Mayeux; Jerome Tamburini; Didier Bouscary Radford-Weiss; Ivan Moura; Patrick Auberger; Norbert Ifrah; Valerie Bardet; Nicolas Chapuis; Alain Schmitt; Laury Poulain; Alexa S. Green; Madalina Uzunov; Olivier Kosmider; Nathalie Jacque; Arnaud Jacquel; Nathalie Neveux; Thiago Trovati Maciel


Archive | 2010

human erythroid malignancies Missense mutation of the erythropoietin receptor is a rare event in

Frederic Feger; Stephanie Gobert; Patrick Mayeux; Nicole Casadevall

Collaboration


Dive into the Patrick Mayeux's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jerome Tamburini

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruno Lioure

University of Strasbourg

View shared research outputs
Top Co-Authors

Avatar

Caroline Elie

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Francis Witz

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yann-Erick Claessens

Cochin University of Science and Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge